In trading on Tuesday, shares of NGM Biopharmaceuticals Inc (Symbol: NGM) crossed below their last reported book value — defined as common shareholder equity per share — of $19.00, changing ...

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 /PRNewswire/ -- NGM Bio, a research-driven biotechnology company that translates powerful biology into transformative medicines, today provided an update ...

NGM Biopharmaceuticals, a Phase 2 biotech developing therapies for NASH and Type 2 Diabetes, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The South San ...

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for ...

NGM has lost some $700 million since it was founded in late 2007. Affiliates of NGM Biopharmaceuticals Inc. earliest venture capital backer and its largest current shareholder plan to pay $1.55 ...